ATLANTA—Recent top-line data from Aviragen Therapeutics' Phase 2b
SPIRITUS trial of vapendavir in moderate to severe asthmatics with a rhinovirus (RV) infection revealed that the compound fell short of its goal. Vapendavir
did not demonstrate a statistically significant reduction in the asthma control questionnaire-6 at day 14, the primary endpoint, for either the 264 mg or 528
mg cohorts compared to placebo.

“We are disappointed that the SPIRITUS trial did not meet its primary
endpoint in this patient population. There was evidence of an antiviral effect in patients that received vapendavir within the first day following the onset
of their symptoms, and as such, we plan to take time to fully analyze the data before making a decision on whether to initiate a study in hematopoietic stem
cell transplant patients, where the ability to stop the progression of the RV infection could be beneficial,” stated Dr. Joseph Patti, president and
CEO of Aviragen.